FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Livermore

Research Profile

Chemicals & Drugs

Procedures

Microbial Sensitivity Tests

Physiology

Geographic Areas

Great Britain

Living Beings

Co-author Network

Publications

TOP 3
Russell Hope; Rachael Adkin; Aiysha Chaudhry; David M Livermore
In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.
David M Livermore; Kazunori Maebashi; Akihiro Morinaka; Shazad Mushtaq; Takashi Ida; Russell Hope
Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes.
Rosy Reynolds; M Warner; Matthew J Ellington; R Hope; David M Livermore; Alasdair P MacGowan
Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Livermore (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Russell Hope; Rachael Adkin; Aiysha Chaudhry; David M Livermore
In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.
International journal of antimicrobial agents 2013;41(3):213-7.
2013: David M Livermore; Kazunori Maebashi; Akihiro Morinaka; Shazad Mushtaq; Takashi Ida; Russell Hope
Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes.
The Journal of antimicrobial chemotherapy 2013;68(1):153-8.
2012: Rosy Reynolds; M Warner; Matthew J Ellington; R Hope; David M Livermore; Alasdair P MacGowan
Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07.
The Journal of antimicrobial chemotherapy 2012;67(12):2912-8.
2012: Hiran Dhanji; Parmina Khan; David M Livermore; Laura J V Piddock; Jennifer L Cottell; Jiancheng Zhang; Neil Woodford
Dissemination of pCT-like IncK plasmids harboring CTX-M-14 extended-spectrum β-lactamase among clinical Escherichia coli isolates in the United Kingdom.
Antimicrobial agents and chemotherapy 2012;56(6):3376-7.
2012: David M Livermore; Shazad Mushtaq; Marina Warner; Kevin Barker; Russell Hope; Neil Woodford
Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).
The Journal of antimicrobial chemotherapy 2012;67(6):1354-8.
2011: Hiran Dhanji; Michel Doumith; Russell Hope; David M Livermore; Neil Woodford
ISEcp1-mediated transposition of linked blaCTX-M-3 and blaTEM-1b from the IncI1 plasmid pEK204 found in clinical isolates of Escherichia coli from Belfast, UK.
The Journal of antimicrobial chemotherapy 2011;66(10):2263-5.
2011: Alejandro Beceiro; Germán Bou; Hiran Dhanji; Michel Doumith; Gordon Downie; Maeve Doyle; Tom Gaulton; Mary Hickey; David M Livermore; Sunil Maharjan; Nelson C Soares; Marina Warner; Neil Woodford
False extended-spectrum {beta}-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins.
The Journal of antimicrobial chemotherapy 2011;66(9):2006-10.
2011: David M Livermore
Discovery research: the scientific challenge of finding new antibiotics.
The Journal of antimicrobial chemotherapy 2011;66(9):1941-4.
2011: Shazad Mushtaq; R Pike; J Pitout; J B Sarma; M Doumith; S Irfan; David M Livermore; N Woodford
Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases.
The Journal of antimicrobial chemotherapy 2011;66(9):2002-5.
2011: Alejandro Beceiro; José Antonio Bengoechea; Germán Bou; Henrik Chart; Hiran Dhanji; Michel Doumith; Michael Hornsey; David M Livermore; Enrique Llobet; Jesús Aranda; Neil Woodford
Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system.
Antimicrobial agents and chemotherapy 2011;55(7):3370-9.
2011: Michael Hornsey; David M Livermore; Nick Loman; Mark J Pallen; Claire P Thomas; Jane F Turton; Anthony Underwood; David W Wareham; Michel Doumith; Matthew J Ellington; Tom Gaulton; Neil Woodford
Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy.
The Journal of antimicrobial chemotherapy 2011;66(7):1499-503.
2011: David M Livermore; Marina Warner; Shazad Mushtaq; Michel Doumith; Jiancheng Zhang; Neil Woodford
What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.
International journal of antimicrobial agents 2011;37(5):415-9.
2011: Hiran Dhanji; Rajesh Patel; Robert Wall; Michel Doumith; Bharat Patel; Russell Hope; David M Livermore; Neil Woodford
Variation in the genetic environments of bla(CTX-M-15) in Escherichia coli from the faeces of travellers returning to the United Kingdom.
The Journal of antimicrobial chemotherapy 2011;66(5):1005-12.
2011: David M Livermore; Shazad Mushtaq; Tue Nguyen; Marina Warner
Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
International journal of antimicrobial agents 2011;37(5):405-9.
2011: David M Livermore; Timothy R Walsh; Mark Toleman; Neil Woodford
Balkan NDM-1: escape or transplant?
The Lancet infectious diseases 2011;11(3):164.
2011: Hiran Dhanji; Niamh M Murphy; Christine Akhigbe; Michel Doumith; Russell Hope; David M Livermore; Neil Woodford
Isolation of fluoroquinolone-resistant O25b:H4-ST131 Escherichia coli with CTX-M-14 extended-spectrum β-lactamase from UK river water.
The Journal of antimicrobial chemotherapy 2011;66(3):512-6.
2011: Hiran Dhanji; Michel Doumith; Paul J Rooney; Maureen C O'Leary; Anne C Loughrey; Russell Hope; Neil Woodford; David M Livermore
Molecular epidemiology of fluoroquinolone-resistant ST131 Escherichia coli producing CTX-M extended-spectrum beta-lactamases in nursing homes in Belfast, UK.
The Journal of antimicrobial chemotherapy 2011;66(2):297-303.
2011: David M Livermore; Shazad Mushtaq; Marina Warner; J-C Zhang; S Maharjan; M Doumith; N Woodford
Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.
The Journal of antimicrobial chemotherapy 2011;66(1):48-53.
2011: David M Livermore; Shazad Mushtaq; Marina Warner; Jiancheng Zhang; Sunil Maharjan; Michel Doumith; Neil Woodford
Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.
Antimicrobial agents and chemotherapy 2011;55(1):390-4.
2010: Russell Hope; Shazad Mushtaq; Dorothy James; T Pllana; Marina Warner; David M Livermore
Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK.
The Journal of antimicrobial chemotherapy 2010;65(12):2602-9.
2010: Hiran Dhanji; Niamh M Murphy; Michel Doumith; Sema Durmus; Susanne Surman Lee; Russell Hope; Neil Woodford; David M Livermore
Cephalosporin resistance mechanisms in Escherichia coli isolated from raw chicken imported into the UK.
The Journal of antimicrobial chemotherapy 2010;65(12):2534-7.
2010: David M Livermore; Shazad Mushtaq; Marina Warner
Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms.
The Journal of antimicrobial chemotherapy 2010;65(11):2382-95.
2010: Shazad Mushtaq; Marina Warner; David M Livermore
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.
The Journal of antimicrobial chemotherapy 2010;65(11):2376-81.
2010: Stephanie A Chisholm; Johan W Mouton; David A Lewis; Tom Nichols; Catherine A Ison; David M Livermore
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
The Journal of antimicrobial chemotherapy 2010;65(10):2141-8.
2010: Hiran Dhanji; Michel Doumith; Olivier Clermont; Erick Denamur; Russell Hope; David M Livermore; Neil Woodford
Real-time PCR for detection of the O25b-ST131 clone of Escherichia coli and its CTX-M-15-like extended-spectrum beta-lactamases.
International journal of antimicrobial agents 2010;36(4):355-8.
2010: Russell Hope; Teresa Pllana; Dorothy James; Marina Warner; David M Livermore
Zone breakpoints, by the CLSI disc method, for 15 μg tigecycline discs corresponding to EUCAST MIC breakpoints.
The Journal of antimicrobial chemotherapy 2010;65(10):2262-4.
2010: Alan P Johnson; Mike Sharland; C M Goodall; R Blackburn; A M Kearns; R Gilbert; Theresa L Lamagni; André Charlett; M Ganner; R Hill; B Cookson; David M Livermore; J Wilson; R Cunney; A Rossney; Georgia Duckworth
Enhanced surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in children in the UK and Ireland.
Archives of disease in childhood 2010;95(10):781-5.
2010: David M Livermore; Shazad Mushtaq; Yigong Ge
Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.
The Journal of antimicrobial chemotherapy 2010;65(9):1972-4.
2010: Shazad Mushtaq; Marina Warner; Jonathan Cloke; Mariya Afzal-Shah; David M Livermore
Performance of the Oxoid M.I.C.Evaluator Strips compared with the Etest assay and BSAC agar dilution.
The Journal of antimicrobial chemotherapy 2010;65(8):1702-11.
2010: Michael Hornsey; Matthew J Ellington; Michel Doumith; Claire P Thomas; Nicola C Gordon; David W Wareham; John Quinn; Karen Lolans; David M Livermore; Neil Woodford
AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii.
The Journal of antimicrobial chemotherapy 2010;65(8):1589-93.
2010: Russell Hope; Teresa Pllana; Marina Warner; David M Livermore
Proposed disc zone breakpoints for doripenem for use with the BSAC disc susceptibility testing method.
The Journal of antimicrobial chemotherapy 2010;65(7):1547-8.
2010: Shazad Mushtaq; Marina Warner; G Williams; I Critchley; David M Livermore
Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.
The Journal of antimicrobial chemotherapy 2010;65(7):1428-32.
2010: Maria Tomás; Michel Doumith; Marina Warner; Jane F Turton; Alejandro Beceiro; German Bou; David M Livermore; Neil Woodford
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Antimicrobial agents and chemotherapy 2010;54(5):2219-24.
2010: Michael Hornsey; Matthew J Ellington; Michel Doumith; Geoff Scott; David M Livermore; Neil Woodford
Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment.
International journal of antimicrobial agents 2010;35(5):478-81.
2010: Stephanie K Henderson-Begg; Carmen L Sheppard; Robert C George; David M Livermore; Lucinda M C Hall
Mutation frequency in antibiotic-resistant and -susceptible isolates of Streptococcus pneumoniae.
International journal of antimicrobial agents 2010;35(4):342-6.
2010: Robert L R Hill; Angela M Kearns; James Nash; Sarah E North; Rachel Pike; Timothy Newson; Neil Woodford; Richard Calver; David M Livermore
Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients.
The Journal of antimicrobial chemotherapy 2010;65(3):442-5.
2010: Michael Hornsey; Matthew J Ellington; Michel Doumith; Sue Hudson; David M Livermore; Neil Woodford
Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome.
The Journal of antimicrobial chemotherapy 2010;65(3):479-82.
2010: Matthew J Ellington; Russell Hope; David M Livermore; Angela M Kearns; Katherine Henderson; Barry D Cookson; Andrew Pearson; Alan P Johnson
Decline of EMRSA-16 amongst methicillin-resistant Staphylococcus aureus causing bacteraemias in the UK between 2001 and 2007.
The Journal of antimicrobial chemotherapy 2010;65(3):446-8.
2009: David M Livermore; Shazad Mushtaq; Yigong Ge; Marina Warner
Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.
International journal of antimicrobial agents 2009;34(5):402-6.
2009: Neil Woodford; Alessandra Carattoli; Edi Karisik; Anthony Underwood; Matthew J Ellington; David M Livermore
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
Antimicrobial agents and chemotherapy 2009;53(10):4472-82.
2009: David M Livermore
beta-Lactamases- the Threat Renews.
Current protein & peptide science 2009;10(5):397-400.
2009: Neil Woodford; David M Livermore
Infections caused by Gram-positive bacteria: a review of the global challenge.
The Journal of infection 2009;59 Suppl 1():S4-16.
2009: David M Livermore
Has the era of untreatable infections arrived?
The Journal of antimicrobial chemotherapy 2009;64 Suppl 1():i29-36.
2009: Paul J Rooney; Maureen C O'Leary; Anne Loughrey; Mark McCalmont; Brian Smyth; Philip Donaghy; Motasim Badri; Neil Woodford; Edi Karisik; David M Livermore
Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli.
The Journal of antimicrobial chemotherapy 2009;64(3):635-41.
2009: David M Livermore; Shazad Mushtaq; Marina Warner
Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms.
The Journal of antimicrobial chemotherapy 2009;64(2):330-5.
2009: Kyungwon Lee; Mi-Na Kim; Tae Yeal Choi; Soung-Eun Cho; Seungok Lee; Dong Hee Whang; Dongeun Yong; Yunsop Chong; Neil Woodford; David M Livermore
Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea.
International journal of antimicrobial agents 2009;33(6):520-4.
2009: David M Livermore
Doripenem: antimicrobial profile and clinical potential.
Diagnostic microbiology and infectious disease 2009;63(4):455-8.
2009: Michel Doumith; Matthew J Ellington; David M Livermore; Neil Woodford
Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK.
The Journal of antimicrobial chemotherapy 2009;63(4):659-67.
2009: David M Livermore; Shazad Mushtaq; Marina Warner; Neil Woodford
Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.
The Journal of antimicrobial chemotherapy 2009;63(4):713-5.
2009: David M Livermore; Paul Tulkens
Temocillin revived.
The Journal of antimicrobial chemotherapy 2009;63(2):243-5.
2008: Neil Woodford; Jiancheng Zhang; Mary E Kaufmann; Susannah Yarde; Maria Del Mar Tomas; Camelia Faris; Madhur S Vardhan; Susan Dawson; Stephen L Cotterill; David M Livermore
Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum beta-lactamases in the United Kingdom.
The Journal of antimicrobial chemotherapy 2008;62(6):1265-8.
2008: Neil Woodford; Jiancheng Zhang; Marina Warner; Mary E Kaufmann; Jorge Matos; Alan Macdonald; Daniel Brudney; David Sompolinsky; Shiri Navon-Venezia; David M Livermore
Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom.
The Journal of antimicrobial chemotherapy 2008;62(6):1261-4.
2008: Siu Ha Lau; Mary E Kaufmann; David M Livermore; Neil Woodford; Geraldine A Willshaw; Tom Cheasty; Katie Stamper; Suganya Reddy; John Cheesbrough; Frederick J Bolton; Andrew J Fox; Mathew Upton
UK epidemic Escherichia coli strains A-E, with CTX-M-15 beta-lactamase, all belong to the international O25:H4-ST131 clone.
The Journal of antimicrobial chemotherapy 2008;62(6):1241-4.
2008: David M Livermore
Future directions with daptomycin.
The Journal of antimicrobial chemotherapy 2008;62 Suppl 3():iii41-iii49.
2008: David J Farrell; David Felmingham; Jemma Shackcloth; Laura Williams; Kirsty Maher; Russell Hope; David M Livermore; Robert C George; Geraldine Brick; Siobhan Martin; Rosy Reynolds
Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007.
The Journal of antimicrobial chemotherapy 2008;62 Suppl 2():ii87-95.
2008: Derek F J Brown; Russell Hope; David M Livermore; Geraldine Brick; Karen Broughton; Robert C George; Rosy Reynolds
Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06.
The Journal of antimicrobial chemotherapy 2008;62 Suppl 2():ii75-85.
2008: Russell Hope; David M Livermore; Geraldine Brick; Mark Lillie; Rosy Reynolds
Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06.
The Journal of antimicrobial chemotherapy 2008;62 Suppl 2():ii65-74.
2008: David M Livermore; Russell Hope; Geraldine Brick; Mark Lillie; Rosy Reynolds
Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06.
The Journal of antimicrobial chemotherapy 2008;62 Suppl 2():ii55-63.
2008: David M Livermore; Russell Hope; Geraldine Brick; Mark Lillie; Rosy Reynolds
Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06.
The Journal of antimicrobial chemotherapy 2008;62 Suppl 2():ii41-54.
2008: David M Livermore; Shazad Mushtaq; Marina Warner; Christine Miossec; Neil Woodford
NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.
The Journal of antimicrobial chemotherapy 2008;62(5):1053-6.
2008: Neil Woodford; Mariya Afzal-Shah; Marina Warner; David M Livermore
In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin.
The Journal of antimicrobial chemotherapy 2008;62(4):766-8.
2008: Dolunay Gülmez; Neil Woodford; Marie-France I Palepou; Shazad Mushtaq; Gokhan Metan; Yusuf Yakupogullari; Sesin Kocagoz; Omrum Uzun; Gulsen Hascelik; David M Livermore
Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss.
International journal of antimicrobial agents 2008;31(6):523-6.
2008: Andrew Hayward; Felicity Knott; Irene Petersen; David M Livermore; Georgia Duckworth; Amir Islam; Anne M Johnson
Increasing hospitalizations and general practice prescriptions for community-onset staphylococcal disease, England.
Emerging infectious diseases 2008;14(5):720-6.
2008: Richard Aschbacher; Michel Doumith; David M Livermore; Clara Larcher; Neil Woodford
Linkage of acquired quinolone resistance (qnrS1) and metallo-beta-lactamase (blaVIM-1) genes in multiple species of Enterobacteriaceae from Bolzano, Italy.
The Journal of antimicrobial chemotherapy 2008;61(3):515-23.
2008: David M Livermore; Russell Hope; Shazad Mushtaq; Marina Warner
Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2008;14 Suppl 1():189-93.
2008: David M Livermore
Defining an extended-spectrum beta-lactamase.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2008;14 Suppl 1():3-10.
2008: Edi Karisik; Matthew J Ellington; David M Livermore; Neil Woodford
Virulence factors in Escherichia coli with CTX-M-15 and other extended-spectrum beta-lactamases in the UK.
The Journal of antimicrobial chemotherapy 2008;61(1):54-8.
2007: David M Livermore; Marina Warner; Shazad Mushtaq
Evaluation of the chromogenic Cica-beta-Test for detecting extended-spectrum, AmpC and metallo-beta-lactamases.
The Journal of antimicrobial chemotherapy 2007;60(6):1375-9.
2007: Matthew J Ellington; R Hope; Jane F Turton; Marina Warner; Neil Woodford; David M Livermore
Detection of qnrA among Enterobacteriaceae from South-East England with extended-spectrum and high-level AmpC beta-lactamases.
The Journal of antimicrobial chemotherapy 2007;60(5):1176-8.
2007: Russell Hope; T Parsons; Shazad Mushtaq; Dorothy James; David M Livermore
Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.
The Journal of antimicrobial chemotherapy 2007;60(4):770-4.
2007: Joanna Empel; Krzysztof Filczak; Agnieszka Mrówka; Waleria Hryniewicz; David M Livermore; Marek Gniadkowski
Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex.
Journal of clinical microbiology 2007;45(9):2829-34.
2007: David M Livermore
The zeitgeist of resistance.
The Journal of antimicrobial chemotherapy 2007;60 Suppl 1():i59-61.
2007: Shazad Mushtaq; Marina Warner; Yigong Ge; Koné Kaniga; David M Livermore
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
The Journal of antimicrobial chemotherapy 2007;60(2):300-11.
2007: David M Livermore; A Pearson
Antibiotic resistance: location, location, location.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2007;13 Suppl 2():7-16.
2007: Maria Virginia Villegas; Juan Nicolas Kattan; Adriana Correa; Karen Lolans; Ana Maria Guzman; Neil Woodford; David M Livermore; John P Quinn
Dissemination of Acinetobacter baumannii clones with OXA-23 Carbapenemase in Colombian hospitals.
Antimicrobial agents and chemotherapy 2007;51(6):2001-4.
2007: David M Livermore
Introduction: the challenge of multiresistance.
International journal of antimicrobial agents 2007;29 Suppl 3():S1-7.
2007: Shazad Mushtaq; Russell Hope; Marina Warner; David M Livermore
Activity of faropenem against cephalosporin-resistant Enterobacteriaceae.
The Journal of antimicrobial chemotherapy 2007;59(5):1025-30.
2007: Neil Woodford; John W T Dallow; Robert L R Hill; Marie-France I Palepou; Rachel Pike; M Elaina Ward; Marina Warner; David M Livermore
Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory.
International journal of antimicrobial agents 2007;29(4):456-9.
2007: Neil Woodford; Robert L R Hill; David M Livermore
In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp.
The Journal of antimicrobial chemotherapy 2007;59(3):582-3.
2007: David M Livermore; Marina Warner; Shazad Mushtaq; Sarah North; Neil Woodford
In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.
Antimicrobial agents and chemotherapy 2007;51(3):1112-4.
2007: Kyungwon Lee; Dongeun Yong; Yeong Seon Choi; Jong Hwa Yum; June Myung Kim; Neil Woodford; David M Livermore; Yunsop Chong
Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases co-mediated by porin loss.
International journal of antimicrobial agents 2007;29(2):201-6.
2007: Matthew J Ellington; James Kistler; David M Livermore; Neil Woodford
Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases.
The Journal of antimicrobial chemotherapy 2007;59(2):321-2.
2007: David M Livermore; Rafael Canton; Marek Gniadkowski; patrice nordmann; Gian Maria Rossolini; Guillaume Arlet; Juan Ayala; Teresa M Coque; Izabela Kern-Zdanowicz; Francesco Luzzaro; Laurent Poirel; Neil Woodford
CTX-M: changing the face of ESBLs in Europe.
The Journal of antimicrobial chemotherapy 2007;59(2):165-74.
2007: Neil Woodford; Suganya Reddy; Elizabeth J Fagan; Robert L R Hill; Katie L Hopkins; Mary E Kaufmann; James Kistler; Marie-France I Palepou; Rachel Pike; M Elaina Ward; John Cheesbrough; David M Livermore
Wide geographic spread of diverse acquired AmpC beta-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland.
The Journal of antimicrobial chemotherapy 2007;59(1):102-5.
2007: Russell Hope; Nicola Potz; Marina Warner; Elizabeth J Fagan; E Arnold; David M Livermore
Efficacy of practised screening methods for detection of cephalosporin-resistant Enterobacteriaceae.
The Journal of antimicrobial chemotherapy 2007;59(1):110-3.
2006: Russell Hope; Marina Warner; Nicola Potz; Elizabeth J Fagan; Dorothy James; David M Livermore
Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England.
The Journal of antimicrobial chemotherapy 2006;58(6):1312-4.
2006: Juliana M Coelho; Jane F Turton; Mary E Kaufmann; Judith Glover; Neil Woodford; Marina Warner; Marie-France I Palepou; Rachel Pike; Tyrone L Pitt; Bharat C Patel; David M Livermore
Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England.
Journal of clinical microbiology 2006;44(10):3623-7.
2006: David M Livermore; Rosy Reynolds; Peter Stephens; Georgia Duckworth; David Felmingham; Alan P Johnson; Stephen Murchan; Olive Murphy; Usha Gungabissoon; Pauline Waight; Richard Pebody; Jemma Shackcloth; Marina Warner; Laura Williams; Robert C George
Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors.
International journal of antimicrobial agents 2006;28(4):273-9.
2006: Matthew J Ellington; David M Livermore; Tyrone L Pitt; Lucinda M C Hall; Neil Woodford
Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance.
The Journal of antimicrobial chemotherapy 2006;58(4):848-52.
2006: David M Livermore; Neil Woodford
The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter.
Trends in microbiology 2006;14(9):413-20.
2006: Edi Karisik; Matthew J Ellington; Rachel Pike; R E Warren; David M Livermore; Neil Woodford
Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from Escherichia coli strains in the United Kingdom.
The Journal of antimicrobial chemotherapy 2006;58(3):665-8.
2006: Edi Karisik; Matthew J Ellington; Rachel Pike; David M Livermore; Neil Woodford
Development of high-level ceftazidime resistance via single-base substitutions of blaCTX-M-3 in hyper-mutable Escherichia coli.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12(8):803-6.
2006: Matthew J Ellington; David M Livermore; Tyrone L Pitt; Lucinda M C Hall; Neil Woodford
Development of extended-spectrum activity in TEM beta-lactamases in hyper-mutable, mutS Escherichia coli.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12(8):800-3.
2006: Nicola Potz; Russell Hope; Marina Warner; Alan P Johnson; David M Livermore
Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England.
The Journal of antimicrobial chemotherapy 2006;58(2):320-6.
2006: Anna Jones; Dilys Morgan; Amanda Walsh; Jane F Turton; David M Livermore; Tyrone L Pitt; Andy Green; Martin Gill; Deborah Mortiboy
Importation of multidrug-resistant Acinetobacter spp infections with casualties from Iraq.
The Lancet infectious diseases 2006;6(6):317-8.
2006: Eugenne Elliott; Adrian J Brink; Johan van Greune; Zia Els; Neil Woodford; Jane Turton; Marina Warner; David M Livermore
In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42(11):e95-8.
2006: Jane F Turton; M Elaina Ward; Neil Woodford; Mary E Kaufmann; Rachel Pike; David M Livermore; Tyrone L Pitt
The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii.
FEMS microbiology letters 2006;258(1):72-7.
2006: Stephanie K Henderson-Begg; David M Livermore; Lucinda M C Hall
Effect of subinhibitory concentrations of antibiotics on mutation frequency in Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy 2006;57(5):849-54.
2006: David M Livermore; Russell Hope; Elizabeth J Fagan; Marina Warner; Neil Woodford; Nicola Potz
Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England.
The Journal of antimicrobial chemotherapy 2006;57(5):1012-4.
2006: Ajay K Sinha; Stephen T Kempley; Elizabeth Price; Bal K Sharma; David M Livermore
Early onset Morganella morganii sepsis in a newborn infant with emergence of cephalosporin resistance caused by depression of AMPC beta-lactamase production..
The Pediatric infectious disease journal 2006;25(4):376-7.
2006: Neil Woodford; Matthew J Ellington; Juliana M Coelho; Jane F Turton; M Elaina Ward; Susan Brown; S G B Amyes; David M Livermore
Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp.
International journal of antimicrobial agents 2006;27(4):351-3.
2006: David M Livermore
Can beta-lactams be re-engineered to beat MRSA?
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12 Suppl 2():11-6.
2006: Derek F J Brown; Nicholas M Brown; Barry D Cookson; Georgia Duckworth; Mark Farrington; Gary L French; L King; D Lewis; David M Livermore; B Macrae; G M Scott; D Williams; Neil Woodford
National glycopeptide-resistant enterococcal bacteraemia surveillance Working Group report to the Department of Health - August 2004.
The Journal of hospital infection 2006;62 Suppl 1():S1-27.
2006: Alexandra Eisner; Elizabeth J Fagan; Gebhard Feierl; Harald H Kessler; Egon Marth; David M Livermore; Neil Woodford
Emergence of Enterobacteriaceae isolates producing CTX-M extended-spectrum beta-lactamase in Austria.
Antimicrobial agents and chemotherapy 2006;50(2):785-7.
2006: Juliana Coelho; Neil Woodford; Mariya Afzal-Shah; David M Livermore
Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents.
Antimicrobial agents and chemotherapy 2006;50(2):756-8.
2005: Russell Hope; Marina Warner; Shazad Mushtaq; M E Ward; T Parsons; David M Livermore
Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines.
The Journal of antimicrobial chemotherapy 2005;56(6):1042-6.
2005: Alan P Johnson; Nicola Potz; Pauline Waight; Usha Gungabissoon; David M Livermore; Richard Pebody; Elizabeth Miller; Robert C George
Susceptibility of pneumococci causing meningitis in England and Wales to first-line antimicrobial agents, 2001-2004.
The Journal of antimicrobial chemotherapy 2005;56(6):1181-2.
2005: Julie R Samuel; Manjula Natarajan; Essam Rizkalla; David M Livermore; Marina Warner; Peter Jenkinson
Disagreements between disc diffusion, and MIC-based susceptibility categorizations of ertapenem versus ESBL producers.
The Journal of antimicrobial chemotherapy 2005;56(5):984-5.
2005: David C Bean; David M Livermore; Iro Papa; Lucinda M C Hall
Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man.
The Journal of antimicrobial chemotherapy 2005;56(5):962-4.
2005: David M Livermore
Tigecycline: what is it, and where should it be used?
The Journal of antimicrobial chemotherapy 2005;56(4):611-4.
2005: David M Livermore; Peter M Hawkey
CTX-M: changing the face of ESBLs in the UK.
The Journal of antimicrobial chemotherapy 2005;56(3):451-4.
2005: David M Livermore
Minimising antibiotic resistance.
The Lancet infectious diseases 2005;5(7):450-9.
2005: Alan P Johnson; Theresa L Lamagni; Martin Wale; Sue Cavendish; Louise Bishop; Neelam Alhaddad; Marina Warner; David M Livermore; Georgia Duckworth; Robert C George
Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) in 2003.
International journal of antimicrobial agents 2005;25(6):539-41.
2005: David M Livermore; Shazad Mushtaq; Marina Warner
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems.
The Journal of antimicrobial chemotherapy 2005;55(3):306-11.
2004: Neil Woodford; Philip M Tierno; Katherine Young; Luke Tysall; Marie-France I Palepou; Elaina Ward; Ronald Painter; Deborah F Suber; Daniel Shungu; Lynn Silver; Kenneth Inglima; John Kornblum; David M Livermore
Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center.
Antimicrobial agents and chemotherapy 2004;48(12):4793-9.
2004: M P Crespo; Neil Woodford; A Sinclair; Mary E Kaufmann; Jane F Turton; Judith Glover; J D Velez; C R Castañeda; M Recalde; David M Livermore
Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia.
Journal of clinical microbiology 2004;42(11):5094-101.
2004: David M Livermore
The need for new antibiotics.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004;10 Suppl 4():1-9.
2004: J Coelho; Neil Woodford; Jane F Turton; David M Livermore
Multiresistant acinetobacter in the UK: how big a threat?
The Journal of hospital infection 2004;58(3):167-9.
2004: Alan P Johnson; Shazad Mushtaq; Marina Warner; David M Livermore
Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
International journal of antimicrobial agents 2004;24(4):315-9.
2004: Neil Woodford; M Elaina Ward; Mary E Kaufmann; Jane F Turton; Elizabeth J Fagan; Dorothy James; Alan P Johnson; Rachel Pike; Marina Warner; T Cheasty; A Pearson; S Harry; J B Leach; A Loughrey; J A Lowes; R E Warren; David M Livermore
Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.
The Journal of antimicrobial chemotherapy 2004;54(4):735-43.
2004: Shazad Mushtaq; Marina Warner; Alan P Johnson; David M Livermore
Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
The Journal of antimicrobial chemotherapy 2004;54(3):617-20.
2004: Shazad Mushtaq; Yigong Ge; David M Livermore
Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
Antimicrobial agents and chemotherapy 2004;48(8):3086-92.
2004: David M Livermore; Sarah Alexander; Bethany Marsden; Dorothy James; Marina Warner; Elizabeth Rudd; Kevin Fenton
Activity of ertapenem against Neisseria gonorrhoeae.
The Journal of antimicrobial chemotherapy 2004;54(1):280-1.
2004: Rosy Reynolds; Nicola Potz; Melissa Colman; Andrea Williams; David M Livermore; Alasdair P MacGowan
Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme.
The Journal of antimicrobial chemotherapy 2004;53(6):1018-32.
2004: Virve I Enne; Peter M Bennett; David M Livermore; Lucinda M C Hall
Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure.
The Journal of antimicrobial chemotherapy 2004;53(6):958-63.
2004: Alan P Johnson; Shazad Mushtaq; Marina Warner; David M Livermore
Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar.
The Journal of antimicrobial chemotherapy 2004;53(5):860-2.
2004: Nicola Potz; Shazad Mushtaq; Alan P Johnson; Caroline J Henwood; Rachel A Walker; E Varey; Marina Warner; Dorothy James; David M Livermore
Reliability of routine disc susceptibility testing by the British Society for Antimicrobial Chemotherapy (BSAC) method.
The Journal of antimicrobial chemotherapy 2004;53(5):729-38.
2004: Sabiha Y Essack; Lucinda M C Hall; David M Livermore
Klebsiella pneumoniae isolate from South Africa with multiple TEM, SHV and AmpC beta-lactamases.
International journal of antimicrobial agents 2004;23(4):398-400.
2004: Shazad Mushtaq; Yigong Ge; David M Livermore
Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.
Antimicrobial agents and chemotherapy 2004;48(4):1313-9.
2004: Nicola Potz; Melissa Colman; Marina Warner; Rosy Reynolds; David M Livermore
False-positive extended-spectrum beta-lactamase tests for Klebsiella oxytoca strains hyperproducing K1 beta-lactamase.
The Journal of antimicrobial chemotherapy 2004;53(3):545-7.
2004: David M Livermore
Can better prescribing turn the tide of resistance?
Nature reviews. Microbiology 2004;2(1):73-8.
2004: Mark Stockdale; Luke Tysall; Alan P Johnson; David M Livermore; Neil Woodford
Low in vitro selection frequencies of enterococcal and staphylococcal mutants resistant to the oxazolidinone AZD2563.
International journal of antimicrobial agents 2004;23(1):88-91.
2004: David M Livermore; Derek F J Brown; John P Quinn; Yehuda Carmeli; David L Paterson; Victor L Yu
Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004;10(1):84-5.
2003: Alan P Johnson; Carmen L Sheppard; S J Harnett; Andrew Birtles; Timothy G Harrison; Nigel P Brenwald; MJ Gill; Rachel A Walker; David M Livermore; Robert C George
Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England.
The Journal of antimicrobial chemotherapy 2003;52(6):953-60.
2003: David M Livermore; Tom Nichols; Theresa L Lamagni; Nicola Potz; Rosy Reynolds; Georgia Duckworth
Ciprofloxacin-resistant Escherichia coli from bacteraemias in England; increasingly prevalent and mostly from men.
The Journal of antimicrobial chemotherapy 2003;52(6):1040-2.
2003: David M Livermore
Overstretching the mutant prevention concentration.
The Journal of antimicrobial chemotherapy 2003;52(4):732; author reply 732-3.
2003: Neil Woodford; Rosy Reynolds; Jane F Turton; Fiona Scott; Alistair Sinclair; Andrea Williams; David M Livermore
Two widely disseminated strains of Enterococcus faecalis highly resistant to gentamicin and ciprofloxacin from bacteraemias in the UK and Ireland.
The Journal of antimicrobial chemotherapy 2003;52(4):711-4.
2003: David M Livermore; Armine M Sefton; Geoffrey M Scott
Properties and potential of ertapenem.
The Journal of antimicrobial chemotherapy 2003;52(3):331-44.
2003: Shazad Mushtaq; Neil Woodford; Nicola Potz; David M Livermore
Detection of CTX-M-15 extended-spectrum beta-lactamase in the United Kingdom.
The Journal of antimicrobial chemotherapy 2003;52(3):528-9.
2003: Jorge A Cepeda; Samantha Hayman; Tony Whitehouse; Christopher Kibbler; David M Livermore; Mervyn Singer; A P R Wilson
Teicoplanin resistance in methicillin-resistant Staphylococcus aureus in an intensive care unit.
The Journal of antimicrobial chemotherapy 2003;52(3):533-4.
2003: Alan P Johnson; Caroline J Henwood; Shazad Mushtaq; Dorothy James; Marina Warner; David M Livermore
Susceptibility of Gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents.
The Journal of hospital infection 2003;54(3):179-87.
2003: Libera Maria Dalla-Costa; Juliana M Coelho; Helena A P H M Souza; Maria E S Castro; Christiane J N Stier; Karin L Bragagnolo; Alvaro Rea-Neto; Sergio R Penteado-Filho; David M Livermore; Neil Woodford
Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil.
Journal of clinical microbiology 2003;41(7):3403-6.
2003: David M Livermore; Shazad Mushtaq; Dorothy James; Nicola Potz; Rachel A Walker; A Charlett; F Warburton; Alan P Johnson; Marina Warner; Caroline J Henwood
In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.
International journal of antimicrobial agents 2003;22(1):14-27.
2003: Kevin A Fenton; Catherine Ison; Alan P Johnson; Elizabeth Rudd; Mehnam Soltani; Iona Martin; Tom Nichols; David M Livermore
Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002.
Lancet 2003;361(9372):1867-9.
2003: David M Livermore
Linezolid in vitro: mechanism and antibacterial spectrum.
The Journal of antimicrobial chemotherapy 2003;51 Suppl 2():ii9-16.
2003: Gioia S Babini; Meifang Yuan; Lucinda M C Hall; David M Livermore
Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases.
The Journal of antimicrobial chemotherapy 2003;51(3):605-12.
2003: David M Livermore
Bacterial resistance: origins, epidemiology, and impact.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36(Suppl 1):S11-23.
2003: David M Livermore
The threat from the pink corner.
Annals of medicine 2003;35(4):226-34.
2002: Richard P Spence; Kevin J Towner; Caroline J Henwood; Dorothy James; Neil Woodford; David M Livermore
Population structure and antibiotic resistance of Acinetobacter DNA group 2 and 13TU isolates from hospitals in the UK.
Journal of medical microbiology 2002;51(12):1107-12.
2002: F Lopez-Otsoa; L Gallego; Kevin J Towner; Luke Tysall; Neil Woodford; David M Livermore
Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain.
Journal of clinical microbiology 2002;40(12):4741-3.
2002: Neil Woodford; Luke Tysall; Cressida Auckland; Mark Stockdale; Andrew J Lawson; Rachel A Walker; David M Livermore
Detection of oxazolidinone-resistant Enterococcus faecalis and Enterococcus faecium strains by real-time PCR and PCR-restriction fragment length polymorphism analysis.
Journal of clinical microbiology 2002;40(11):4298-300.
2002: Alan P Johnson; Luke Tysall; Mark Stockdale; Neil Woodford; Mary E Kaufmann; Marina Warner; David M Livermore; F Asboth; F J Allerberger
Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2002;21(10):751-4.
2002: David M Livermore; Dorothy James; Georgia Duckworth; Peter Stephens
Fusidic-acid use and resistance.
Lancet 2002;360(9335):806.
2002: Alan P Johnson; Marina Warner; David M Livermore
In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
The Journal of antimicrobial chemotherapy 2002;50(1):89-93.
2002: Virve I Enne; Anna King; David M Livermore; Lucinda M C Hall
Sulfonamide resistance in Haemophilus influenzae mediated by acquisition of sul2 or a short insertion in chromosomal folP.
Antimicrobial agents and chemotherapy 2002;46(6):1934-9.
2002: David M Livermore; Dorothy James; Mark Reacher; Catriona Graham; Tom Nichols; Peter Stephens; Alan P Johnson; Robert C George
Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999.
Emerging infectious diseases 2002;8(5):473-8.
2002: Kyungwon Lee; Jong Back Lim; Jong Hwa Yum; Dongeun Yong; Yunsop Chong; June Myung Kim; David M Livermore
bla(VIM-2) cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital.
Antimicrobial agents and chemotherapy 2002;46(4):1053-8.
2002: Caroline J Henwood; Tess Gatward; Marina Warner; Dorothy James; Mark Stockdale; Richard P Spence; Kevin J Towner; David M Livermore; Neil Woodford
Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).
The Journal of antimicrobial chemotherapy 2002;49(3):479-87.
2002: David M Livermore
Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34(5):634-40.
2002: David M Livermore
The impact of carbapenemases on antimicrobial development and therapy.
Current opinion in investigational drugs (London, England : 2000) 2002;3(2):218-24.
2002: David M Livermore; Marc Jean Struelens; J Amorim; Fernando Baquero; J Bille; R Canton; S Henning; S Gatermann; A Marchese; H Mittermayer; Claire Nonhoff; K J Oakton; F Praplan; H Ramos; G C Schito; J Van Eldere; J Verhaegen; J Verhoef; M R Visser
Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests.
The Journal of antimicrobial chemotherapy 2002;49(2):289-300.
2002: Alan P Johnson; Marina Warner; Michael Carter; David M Livermore
In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci.
Antimicrobial agents and chemotherapy 2002;46(2):321-6.
2002: Luke Tysall; Mark Stockdale; Paul R Chadwick; Marie-France I Palepou; Kevin J Towner; David M Livermore; Neil Woodford
IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK.
The Journal of antimicrobial chemotherapy 2002;49(1):217-8.
2002: Alan Patrick Gibb; Chanwit Tribuddharat; Richard A Moore; Thomas J Louie; Wally Krulicki; David M Livermore; Marie-France I Palepou; Neil Woodford
Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7).
Antimicrobial agents and chemotherapy 2002;46(1):255-8.
2001: Alan P Johnson; David M Livermore; G S Tillotson
Antimicrobial susceptibility of Gram-positive bacteria: what's current, what's anticipated?
The Journal of hospital infection 2001;49 Suppl A():S3-11.
2001: David M Livermore; M Warner; Lucinda M C Hall; Virve I Enne; Steven Projan; Paul Dunman; S L Wooster; G Harrison
Antibiotic resistance in bacteria from magpies (Pica pica) and rabbits (Oryctolagus cuniculus) from west Wales.
Environmental microbiology 2001;3(10):658-61.
2001: David M Livermore; K J Oakton; M W Carter; Marina Warner
Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases.
Antimicrobial agents and chemotherapy 2001;45(10):2831-7.
2001: Neil Woodford; David M Livermore
Can we beat MRSA now we know its genome sequence?
The Lancet infectious diseases 2001;1(1):9-10.
2001: David M Livermore; T G Winstanley; K P Shannon
Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes.
The Journal of antimicrobial chemotherapy 2001;48 Suppl 1():87-102.
2001: David M Livermore; D F Brown
Detection of beta-lactamase-mediated resistance.
The Journal of antimicrobial chemotherapy 2001;48 Suppl 1():59-64.
2001: Alan P Johnson; Hazel M Aucken; S Cavendish; Mark Ganner; Martin Wale; Marina Warner; David M Livermore; Barry D Cookson
Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS).
The Journal of antimicrobial chemotherapy 2001;48(1):143-4.
2001: Tse Hsien Koh; Li-Hwei Sng; Gioia S Babini; Neil Woodford; David M Livermore; Lucinda M C Hall
Carbapenem-resistant Klebsiella pnuemoniae in Singapore producing IMP-1 beta-lactamase and lacking an outer membrane protein.
Antimicrobial agents and chemotherapy 2001;45(6):1939-40.
2001: Caroline J Henwood; David M Livermore; Dorothy James; Marina Warner
Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test.
The Journal of antimicrobial chemotherapy 2001;47(6):789-99.
2001: David M Livermore; M W Carter; Simone Bagel; Bernd Wiedemann; Fernando Baquero; E Loza; Hubert P Endtz; Nicole van den Braak; C J Fernandes; L Fernandes; N Frimodt-Moller; L S Rasmussen; Helen Giamarellou; E Giamarellos-Bourboulis; V Jarlier; J Nguyen; C E Nord; Marc Jean Struelens; Claire Nonhoff; J Turnidge; J Bell; R Zbinden; S Pfister; L Mixson; D L Shungu
In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia.
Antimicrobial agents and chemotherapy 2001;45(6):1860-7.
2001: Alan P Johnson; Marina Warner; David M Livermore
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
International journal of antimicrobial agents 2001;17(5):377-81.
2001: Virve I Enne; David M Livermore; P Stephens; Lucinda M C Hall
Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction.
Lancet 2001;357(9265):1325-8.
2001: Alan P Johnson; Marina Warner; Robert C George; David M Livermore
Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.
The Journal of antimicrobial chemotherapy 2001;47(4):411-5.
2001: F Danel; J M Frère; David M Livermore
Evidence of dimerisation among class D beta-lactamases: kinetics of OXA-14 beta-lactamase.
Biochimica et biophysica acta 2001;1546(1):132-42.
2001: David M Livermore
Of Pseudomonas, porins, pumps and carbapenems.
The Journal of antimicrobial chemotherapy 2001;47(3):247-50.
2001: YIU WAI CHU; Mariya Afzal-Shah; Elizabeth T S Houang; M I Palepou; Donald J Lyon; Neil Woodford; David M Livermore
IMP-4, a novel metallo-beta-lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998.
Antimicrobial agents and chemotherapy 2001;45(3):710-4.
2001: Alan P Johnson; Marina Warner; K Broughton; Dorothy James; A Efsratiou; Robert C George; David M Livermore
Antibiotic susceptibility of streptococci and related genera causing endocarditis: analysis of UK reference laboratory referrals, January 1996 to March 2000.
BMJ (Clinical research ed.) 2001;322(7283):395-6.
2001: Mariya Afzal-Shah; Neil Woodford; David M Livermore
Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii.
Antimicrobial agents and chemotherapy 2001;45(2):583-8.
2001: M Yuan; Lucinda M C Hall; J Hoogkamp-Korstanje; David M Livermore
SHV-14, a novel beta-lactamase variant in Klebsiella pneumoniae isolates from Nijmegen, The Netherlands.
Antimicrobial agents and chemotherapy 2001;45(1):309-11.
2001: Sabiha Y Essack; Lucinda M C Hall; D G Pillay; M L McFadyen; David M Livermore
Complexity and diversity of Klebsiella pneumoniae strains with extended-spectrum beta-lactamases isolated in 1994 and 1996 at a teaching hospital in Durban, South Africa.
Antimicrobial agents and chemotherapy 2001;45(1):88-95.
2000: Caroline J Henwood; David M Livermore; Alan P Johnson; Dorothy James; Marina Warner; A Gardiner
Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.
The Journal of antimicrobial chemotherapy 2000;46(6):931-40.
2000: David M Livermore
Antibiotic resistance in staphylococci.
International journal of antimicrobial agents 2000;16 Suppl 1():S3-10.
2000: M W Carter; K J Oakton; Marina Warner; David M Livermore
Detection of extended-spectrum beta-lactamases in klebsiellae with the Oxoid combination disk method.
Journal of clinical microbiology 2000;38(11):4228-32.
2000: David M Livermore; Neil Woodford
Carbapenemases: a problem in waiting?
Current opinion in microbiology 2000;3(5):489-95.
2000: Hazel M Aucken; Marina Warner; Mark Ganner; Alan P Johnson; JF Richardson; Barry D Cookson; David M Livermore
Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus.
The Journal of antimicrobial chemotherapy 2000;46(4):639-40.
2000: David M Livermore; Peter Stephens; J Weinberg; Alan P Johnson; T Gifford; D Northcott; Dorothy James; Robert C George; DC Speller
Regional variation in ampicillin and trimethoprim resistance in Escherichia coli in England from 1990 to 1997, in relation to antibacterial prescribing.
The Journal of antimicrobial chemotherapy 2000;46(3):411-22.
2000: David M Livermore
Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?
The Journal of antimicrobial chemotherapy 2000;46(3):347-50.
2000: Alan P Johnson; Marina Warner; G Hallas; David M Livermore
Susceptibility to quinupristin/dalfopristin and other antibiotics of vancomycin-resistant enterococci from the UK, 1997 to mid-1999.
The Journal of antimicrobial chemotherapy 2000;46(1):125-8.
2000: Neil Woodford; Marie-France I Palepou; GS Babini; B Holmes; David M Livermore
Carbapenemases of Chryseobacterium (Flavobacterium) meningosepticum: distribution of blaB and characterization of a novel metallo-beta-lactamase gene, blaB3, in the type strain, NCTC 10016.
Antimicrobial agents and chemotherapy 2000;44(6):1448-52.
2000: M Yuan; Lucinda M C Hall; P H Savelkoul; Christina M.J.E, Vandenbroucke-Grauls; David M Livermore
SHV-13, a novel extended-spectrum beta-lactamase, in Klebsiella pneumoniae isolates from patients in an intensive care unit in Amsterdam.
Antimicrobial agents and chemotherapy 2000;44(4):1081-4.
2000: Athanassios Tsakris; Spyros Pournaras; Neil Woodford; Marie-France I Palepou; GS Babini; John Douboyas; David M Livermore
Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece.
Journal of clinical microbiology 2000;38(3):1290-2.
2000: Alan P Johnson; Marina Warner; David M Livermore
Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.
The Journal of antimicrobial chemotherapy 2000;45(2):225-30.
2000: David M Livermore; E J Threlfall; Mark Reacher; Alan P Johnson; Dorothy James; T Cheasty; A Shah; F Warburton; A V Swan; J Skinner; A Graham; D C Speller
Are routine sensitivity test data suitable for the surveillance of resistance? Resistance rates amongst Escherichia coli from blood and CSF from 1991-1997, as assessed by routine and centralized testing.
The Journal of antimicrobial chemotherapy 2000;45(2):205-11.
2000: GS Babini; David M Livermore
Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998.
The Journal of antimicrobial chemotherapy 2000;45(2):183-9.
2000: Mark Reacher; A Shah; David M Livermore; Martin Wale; C Graham; Alan P Johnson; H Heine; MA Monnickendam; K F Barker; D James; Robert C George
Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis.
BMJ (Clinical research ed.) 2000;320(7229):213-6.
2000: GS Babini; David M Livermore
Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases.
The Journal of antimicrobial chemotherapy 2000;45(1):105-9.
1999: Alan P Johnson; David M Livermore
Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal.
Lancet 1999;354(9195):2012-3.
1999: Tse Hsien Koh; Gioia S Babini; Neil Woodford; Li-Hwei Sng; Lucinda M C Hall; David M Livermore
Carbapenem-hydrolysing IMP-1 beta-lactamase in Klebsiella pneumoniae from Singapore.
Lancet 1999;353(9170):2162.
1999: F Danel; Lucinda M C Hall; B Duke; D Gur; David M Livermore
OXA-17, a further extended-spectrum variant of OXA-10 beta-lactamase, isolated from Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1999;43(6):1362-6.
1999: David M Livermore; H Y Chen
Quality of antimicrobial susceptibility testing in the UK: a Pseudomonas aeruginosa survey revisited.
The Journal of antimicrobial chemotherapy 1999;43(4):517-22.
1999: F Danel; Lucinda M C Hall; David M Livermore
Laboratory mutants of OXA-10 beta-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy 1999;43(3):339-44.
1998: F Danel; Lucinda M C Hall; D Gur; David M Livermore
OXA-16, a further extended-spectrum variant of OXA-10 beta-lactamase, from two Pseudomonas aeruginosa isolates.
Antimicrobial agents and chemotherapy 1998;42(12):3117-22.
1998: Neil Woodford; Marie-France I Palepou; GS Babini; J Bates; David M Livermore
Carbapenemase-producing Pseudomonas aeruginosa in UK.
Lancet 1998;352(9127):546-7.
1998: M Yuan; Hazel M Aucken; Lucinda M C Hall; Tyrone L Pitt; David M Livermore
Epidemiological typing of klebsiellae with extended-spectrum beta-lactamases from European intensive care units.
The Journal of antimicrobial chemotherapy 1998;41(5):527-39.
1998: Y F Chiew; S F Yeo; Lucinda M C Hall; David M Livermore
Can susceptibility to an antimicrobial be restored by halting its use? The case of streptomycin versus Enterobacteriaceae.
The Journal of antimicrobial chemotherapy 1998;41(2):247-51.
1998: G S Babini; F Danel; S D Munro; P A Micklesen; David M Livermore
Unusual tazobactam-sensitive AmpC beta-lactamase from two Escherichia coli isolates.
The Journal of antimicrobial chemotherapy 1998;41(1):115-8.
1997: H E Villar; F Danel; David M Livermore
Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams.
The Journal of antimicrobial chemotherapy 1997;40(3):365-70.
1997: David M Livermore; H Y Chen
Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
The Journal of antimicrobial chemotherapy 1997;40(3):335-43.
1997: David M Livermore
Acquired carbapenemases.
The Journal of antimicrobial chemotherapy 1997;39(6):673-6.
1997: F Danel; Lucinda M C Hall; D Gur; David M Livermore
OXA-15, an extended-spectrum variant of OXA-2 beta-lactamase, isolated from a Pseudomonas aeruginosa strain.
Antimicrobial agents and chemotherapy 1997;41(4):785-90.
1997: I B Ibrahim-Elmagboul; David M Livermore
Sensitivity testing of ciprofloxacin for Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy 1997;39(3):309-17.
1996: David M Livermore; M Yuan
Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
The Journal of antimicrobial chemotherapy 1996;38(3):409-24.
1995: David M Livermore
beta-Lactamases in laboratory and clinical resistance.
Clinical microbiology reviews 1995;8(4):557-84.
1995: H Y Chen; M Yuan; David M Livermore
Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993.
Journal of medical microbiology 1995;43(4):300-9.
1995: Haluk Vahaboglu; L M Hall; L Mulazimoglu; S Dodanli; I Yildirim; David M Livermore
Resistance to extended-spectrum cephalosporins, caused by PER-1 beta-lactamase, in Salmonella typhimurium from Istanbul, Turkey.
Journal of medical microbiology 1995;43(4):294-9.
1995: F Danel; L M Hall; D Gur; David M Livermore
OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1995;39(8):1881-4.
1995: H Y Chen; M Yuan; I B Ibrahim-Elmagboul; David M Livermore
National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy 1995;35(4):521-34.
1995: F Danel; L M Hall; D Gur; HE Akalin; David M Livermore
Transferable production of PER-1 beta-lactamase in Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy 1995;35(2):281-94.
1995: David M Livermore
Bacterial resistance to carbapenems.
Advances in experimental medicine and biology 1995;390():25-47.
1994: C P Fung; S F Yeo; David M Livermore
Extraction of beta-lactamase from Moraxella catarrhalis.
The Journal of antimicrobial chemotherapy 1994;34(1):183-4.
1994: G Bonfiglio; David M Livermore
Inoculum effects on Etests and agar dilution minimum inhibitory concentrations. Piperacillin and piperacillin-tazobactam against Staphylococcus aureus.
Diagnostic microbiology and infectious disease 1994;19(3):163-6.
1994: H Y Chen; David M Livermore
In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
The Journal of antimicrobial chemotherapy 1994;33(5):949-58.
1994: S F Yeo; David M Livermore
Effect of inoculum size on the in-vitro susceptibility to beta-lactam antibiotics of Moraxella catarrhalis isolates of different beta-lactamase types.
Journal of medical microbiology 1994;40(4):252-5.
1994: S F Yeo; David M Livermore
Comparative in-vitro activity of biapenem and other carbapenems against Haemophilus influenzae isolates with known resistance mechanisms to ampicillin.
The Journal of antimicrobial chemotherapy 1994;33(4):861-5.
1994: G Bonfiglio; David M Livermore
beta-Lactamase types amongst Staphylococcus aureus isolates in relation to susceptibility to beta-lactamase inhibitor combinations.
The Journal of antimicrobial chemotherapy 1994;33(3):465-81.
1994: H Y Chen; David M Livermore
Comparative in-vitro activity of biapenem against enterobacteria with beta-lactamase-mediated antibiotic resistance.
The Journal of antimicrobial chemotherapy 1994;33(3):453-64.
1994: C P Fung; S F Yeo; David M Livermore
Susceptibility of Moraxella catarrhalis isolates to beta-lactam antibiotics in relation to beta-lactamase pattern.
The Journal of antimicrobial chemotherapy 1994;33(2):215-22.
1993: H Y Chen; David M Livermore
Activity of cefepime and other beta-lactam antibiotics against permeability mutants of Escherichia coli and Klebsiella pneumoniae.
The Journal of antimicrobial chemotherapy 1993;32 Suppl B():63-74.
1993: G Bonfiglio; David M Livermore
Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
The Journal of antimicrobial chemotherapy 1993;32(3):431-44.
1993: H Y Chen; G Bonfiglio; M Allen; D Piper; T Edwardson; D McVey; David M Livermore
Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
The Journal of antimicrobial chemotherapy 1993;32(2):247-66.
1993: L M Hall; David M Livermore; D Gur; Murat Akova; HE Akalin
OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1993;37(8):1637-44.
1993: David M Livermore
Determinants of the activity of beta-lactamase inhibitor combinations.
The Journal of antimicrobial chemotherapy 1993;31 Suppl A():9-21.
1992: P Y Liu; D Gur; L M Hall; David M Livermore
Survey of the prevalence of beta-lactamases amongst 1000 gram-negative bacilli isolated consecutively at the Royal London Hospital.
The Journal of antimicrobial chemotherapy 1992;30(4):429-47.
1992: Deniz Gür; Tyrone L Pitt; L M Hall; HE Akalin; David M Livermore
Diversity of klebsiellae with extended-spectrum beta-lactamases at a Turkish university hospital.
The Journal of hospital infection 1992;22(2):163-7.
1992: David M Livermore
Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1992;36(9):2046-8.
1992: David M Livermore; J E Corkill
Effects of CO2 and pH on inhibition of TEM-1 and other beta-lactamases by penicillanic acid sulfones.
Antimicrobial agents and chemotherapy 1992;36(9):1870-6.
1992: David M Livermore
Carbapenemases.
The Journal of antimicrobial chemotherapy 1992;29(6):609-13.
1991: G Bonfiglio; David M Livermore
Effect of media composition on the susceptibility of Xanthomonas maltophilia to beta-lactam antibiotics.
The Journal of antimicrobial chemotherapy 1991;28(6):837-42.
1991: Murat Akova; G Bonfiglio; David M Livermore
Susceptibility to beta-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high- and low-level constitutive expression of L1 and L2 beta-lactamases.
Journal of medical microbiology 1991;35(4):208-13.
1991: P S Seetulsingh; L M Hall; David M Livermore
Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989.
The Journal of antimicrobial chemotherapy 1991;27(6):749-59.
1991: David M Livermore; P Seetulsingh
Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
The Journal of antimicrobial chemotherapy 1991;27(6):761-7.
1991: David M Livermore; K W Davy
Invalidity for Pseudomonas aeruginosa of an accepted model of bacterial permeability to beta-lactam antibiotics.
Antimicrobial agents and chemotherapy 1991;35(5):916-21.
1991: David M Livermore
Mechanisms of resistance to beta-lactam antibiotics.
Scandinavian journal of infectious diseases. Supplementum 1991;78():7-16.
1990: M Powell; David M Livermore
Selection and transformation of non-beta-lactamase-mediated insusceptibility to beta-lactams in Haemophilus influenzae: lack of cross-resistance between carbapenems and other agents.
The Journal of antimicrobial chemotherapy 1990;26(6):741-7.
1990: David M Livermore; M J Wood
Mechanisms and clinical significance of resistance to new beta-lactam antibiotics.
British journal of hospital medicine 1990;44(4):252-8, 261-3.
1990: P J Wu; David M Livermore
Response of chemostat cultures of Pseudomonas aeruginosa to carbapenems and other beta-lactams.
The Journal of antimicrobial chemotherapy 1990;25(6):891-902.
1990: Y J Yang; P J Wu; David M Livermore
Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates.
Antimicrobial agents and chemotherapy 1990;34(5):755-8.
1990: Murat Akova; Y Yang; David M Livermore
Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
The Journal of antimicrobial chemotherapy 1990;25(2):199-208.
1990: David M Livermore
Antibiotic uptake and transport by bacteria.
Scandinavian journal of infectious diseases. Supplementum 1990;74():15-22.
1989: M Powell; K W Davy; David M Livermore
Reaction products of chloramphenicol acetyltransferases from enterobacteria and Haemophilus influenzae.
The Journal of antimicrobial chemotherapy 1989;24(6):897-903.
1989: David M Livermore; Murat Akova; P J Wu; Y J Yang
Clavulanate and beta-lactamase induction.
The Journal of antimicrobial chemotherapy 1989;24 Suppl B():23-33.
1989: Y J Yang; David M Livermore
Interactions of meropenem with class I chromosomal beta-lactamases.
The Journal of antimicrobial chemotherapy 1989;24 Suppl A():207-17.
1989: Y Yang; David M Livermore
Interactions of FCE 22101 with class I beta-lactamases.
The Journal of antimicrobial chemotherapy 1989;23 Suppl C():85-94.
1989: A A Said; David M Livermore
In-vitro interactions of FCE 22101 with aminoglycosides against gram-negative rods.
The Journal of antimicrobial chemotherapy 1989;23 Suppl C():103-8.
1989: J Brown; Y J Yang; David M Livermore
In-vitro activity of tigemonam, an oral monobactam, against gram-negative rods, including variants in beta-lactamase-production.
The Journal of antimicrobial chemotherapy 1989;23(2):201-7.
1988: P Gargalianos; B A Oppenheim; P Skepastianos; David M Livermore; R J Williams
Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics.
The Journal of antimicrobial chemotherapy 1988;22(6):841-8.
1988: M Powell; David M Livermore
Mechanisms of chloramphenicol resistance in Haemophilus influenzae in the United Kingdom.
Journal of medical microbiology 1988;27(2):89-93.
1988: Y Yang; David M Livermore
Activity of temocillin and other penicillins against beta-lactamase-inducible and -stably derepressed enterobacteria.
The Journal of antimicrobial chemotherapy 1988;22(3):299-306.
1988: Y J Yang; David M Livermore
Chromosomal beta-lactamase expression and resistance to beta-lactam antibiotics in Proteus vulgaris and Morganella morganii.
Antimicrobial agents and chemotherapy 1988;32(9):1385-91.
1988: David M Livermore
Permeation of beta-lactam antibiotics into Escherichia coli, Pseudomonas aeruginosa, and other gram-negative bacteria.
Reviews of infectious diseases 1988;10(4):691-8.
1988: Y J Yang; David M Livermore; R J Williams
Chromosomal beta-lactamase expression and antibiotic resistance in Enterobacter cloacae.
Journal of medical microbiology 1988;25(3):227-33.
1987: A A Said; David M Livermore; R J Williams
Expression of H1 outer-membrane protein of Pseudomonas aeruginosa in relation to sensitivity to EDTA and polymyxin B.
Journal of medical microbiology 1987;24(3):267-74.
1987: David M Livermore
Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods.
European journal of clinical microbiology 1987;6(4):439-45.
1981: David M Livermore; R J Williams; JD Williams
In-vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal beta-lactamases.
The Journal of antimicrobial chemotherapy 1981;8 Suppl B():163-7.